TNYA

Business Context and Reporting Period

Tenaya Therapeutics, Inc. (TNYA) is a clinical-stage biotechnology company focused on developing curative therapies for heart disease. The reporting period covers the three months ended March 31, 2025. The company has no approved products and has not generated any revenue to date. Its lead product candidates include TN-201 (gene therapy for hypertrophic cardiomyopathy), TN-401 (gene therapy for arrhythmogenic right ventricular cardiomyopathy), and TN-301 (small molecule for heart failure with preserved ejection fraction).

Key Financial Metrics

Material Changes vs. Prior Period

• Expense Reduction: Total operating expenses decreased by 18% ($6.2 million) year-over-year, driven by a 16% decrease in R&D expenses and a 26% decrease in G&A expenses. This reduction is attributed to the 2024 Workforce Reduction and lower clinical support costs.
• Capital Raise: In March 2025, the company completed a follow-on offering of 75 million units (common stock and warrants), raising net proceeds of approximately $48.8 million. Additionally, $0.9 million was raised via an "at-the-market" (ATM) offering in January 2025.
• Liquidity Position: Cash and cash equivalents increased significantly from $4.3 million at year-end 2024 to $53.8 million at March 31, 2025, bolstered by the equity financing and proceeds from the maturity and sale of marketable securities.
• Stock-Based Compensation: Total stock-based compensation was $3.7 million, a decrease from $4.2 million in the prior year, though it included $0.4 million of incremental expense related to a stock option repricing event in January 2025.

Guidance, Outlook, and Risks

• Outlook: Management believes that existing cash, investments, and the $22.5 million available under a loan agreement with Silicon Valley Bank (SVB) will fund operations for at least the next twelve months. The company is prioritizing data generation from the MyPEAK-1 (TN-201) and RIDGE-1 (TN-401) clinical trials.
• Cost Containment: In March 2025, the company announced a workforce reduction (2025 Workforce Reduction) to align costs with clinical trial focus. Estimated aggregate charges are $1.6 million to $2.7 million, with $1.0 million recognized in Q1 2025.
• Grant Funding: The company was awarded an $8 million grant from the California Institute for Regenerative Medicine (CIRM) to support the TN-401 clinical trial. $0.6 million was received in April 2025.
• Nasdaq Listing Risk: On April 15, 2025, the company received notice from Nasdaq that it failed to meet the minimum bid price requirement of $1.00 per share. The company has a 180-day compliance period to regain compliance or risk delisting.
• Debt Facility: The company has a loan agreement with SVB allowing for up to $45 million in term loans. As of March 31, 2025, no funds have been drawn, but $22.5 million is available at the company's discretion.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $88.2 million cash balance combined with the SVB loan facility to fund operations through the critical data readouts expected in the second half of 2025 and into 2026.
• Nasdaq Compliance: Monitor the company's ability to regain the $1.00 minimum bid price within the 180-day grace period to avoid delisting, which could impact liquidity and investor confidence.
• Clinical Trial Progress: Track enrollment and safety data for the MyPEAK-1 (TN-201) and RIDGE-1 (TN-401) trials, as these are the primary drivers of future value and potential partnership opportunities.
• Dilution Risk: Assess the impact of the recent issuance of 75 million shares and 112.5 million warrants (Series A and B) on existing shareholder dilution and future capital raising needs.
• Workforce Reduction Impact: Evaluate whether the cost savings from the 2025 Workforce Reduction are sufficient to extend the runway without compromising the execution of clinical trials.